+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07654400

Evaluation of BL-M14D1 Combined With Atezolizumab for Treating Extensive-stage Small Cell Lung Cancer

Led by Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Updated on 2026-11-02

36

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of BL-M14D1 combined with Atezolizumab in people with extensive-stage small cell lung cancer. This Phase II clinical study aims to understand how this combination treatment works in patients whose cancer is incurable or for whom no standard treatment exists. Participants receive intravenous infusions of BL-M14D1 and Atezolizumab every 3 weeks for an initial treatment cycle. Those who benefit clinically may continue receiving additional cycles until the disease progresses, intolerable side effects occur, or other reasons lead to stopping treatment. During the study, participants will be monitored for tumor response and side effects over up to 12 months. Assessments include measuring tumor lesions, survival rates, and collecting blood samples to study drug levels, immune responses, and potential drug interactions. Safety is closely observed throughout the treatment period.

CONDITIONS

Brief Title

A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

Research Team

S

Sa Xiao, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here